Filing summary
Entity and period: The supplied filing is OncoCyte Corporation’s Form 10-K for the fiscal year ended December 31, 2017, filed April 2, 2018. This differs from the request metadata naming Insight Molecular Diagnostics Inc.; the filing itself identifies OncoCyte as the registrant. It is an annual report, not a standalone fourth-quarter report.
Business context
OncoCyte is a pre-revenue molecular diagnostics developer focused on liquid-biopsy cancer tests. Its lead program, DetermaVu, is a blood-based confirmatory test for lung cancer in patients with suspicious lung nodules. The company devoted substantially all of its 2017 development effort to DetermaVu; breast and bladder programs were deprioritized. OncoCyte ceased to be a consolidated BioTime subsidiary on February 17, 2017, although BioTime retained significant influence and provided facilities and services.
Financial performance and liquidity
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $7.17 million | $5.68 million |
| General and administrative expense | $9.23 million | $4.27 million |
| Sales and marketing expense | $2.44 million | $1.20 million |
| Net loss | $19.38 million | $11.17 million |
| Basic and diluted loss per share | $0.64 | $0.42 |
| Net cash used in operating activities | $13.39 million | $7.52 million |
With no revenue, operating margins are not meaningful. At year-end, cash and cash equivalents were $7.60 million, BioTime shares held as available-for-sale securities were valued at $0.76 million, total assets were $10.22 million, total liabilities were $5.81 million, and stockholders’ equity was $4.40 million. Current assets of $8.53 million exceeded current liabilities of $4.45 million. The accumulated deficit was $54.68 million.
Debt included a Silicon Valley Bank loan with $1.87 million recorded net of deferred financing costs, plus capital-lease liabilities. The bank loan bears floating interest and matures April 1, 2020; substantially all assets other than intellectual property secure it. The company reported compliance with the loan agreement at filing.
Management said year-end resources, together with post-year-end financing, were expected to fund current operations for at least twelve months from the financial-statement issuance date. On March 28, 2018, OncoCyte agreed to sell 7.94 million shares at $1.26 per share for $10.0 million gross proceeds: $8.0 million had been received, with a further $2.0 million irrevocably committed by April 30, 2018. Additional capital may be needed for expanded development or commercialization.
Material changes and unusual items
- Net loss increased by about 74% year over year, while operating cash use rose by about 78%.
- G&A increased substantially, including a $4.07 million noncash charge for warrants issued to induce investors to exercise earlier warrants. The inducement generated $7.77 million in warrant-exercise proceeds.
- R&D expense rose 26%, chiefly reflecting DetermaVu development, clinical and laboratory costs, and CLIA laboratory expenses. Sales and marketing expense more than doubled as the company prepared for a potential launch.
- Cash declined from $10.17 million to $7.60 million. Sale of BioTime shares generated $0.93 million net proceeds and a reported $0.31 million loss; proceeds were used to reduce amounts owed to BioTime and affiliates.
- BioTime’s ownership fell below 50% in February 2017, ending financial-statement consolidation. Comparisons should be read with this change and related-party cost allocations in mind.
Outlook, risks, and contingencies
- DetermaVu development delay: Initial clinical-validation testing in November 2017 produced inconsistent results attributed to variation in consumable lots on the original testing platform. OncoCyte was evaluating alternatives and expected to select a platform in Q2 2018. It targeted clinical validation in the latter part of 2018, conditional on successful platform selection and further R&D and analytical validation. The filing emphasizes that successful development and commercialization were not assured.
- Promising but preliminary test data: An R&D validation study of 299 samples reported 97% sensitivity and 73% specificity. A revised algorithm tested on approximately 60 samples showed equivalent or better AUC, but the filing cautions that the sample was small and uncertainty wide. These results are not completed clinical validation or evidence of commercial performance.
- Commercialization and reimbursement: The company had no marketed tests and no operating revenue. Launch would require additional sales, market-access, billing, and support capabilities. Lack of Medicare or commercial-payer coverage could constrain physician and patient uptake; the timing and amount of reimbursement were uncertain.
- Funding and dilution: OncoCyte expected continued losses and negative cash flow and anticipated needing additional financing. Further equity issuance could dilute shareholders; financing might not be available on acceptable terms.
- Regulatory and operational risks: The company expected to use the CLIA laboratory-developed-test pathway initially, but future FDA oversight of LDTs remained uncertain. It also faced state laboratory licensing requirements, dependence on reagent and platform suppliers, patent and license risks, and reliance on BioTime for facilities and administrative support.
- Other: Wistar’s lung-cancer license entails 3%–5% royalties, minimum annual royalties, maintenance fees, milestones, and development obligations. No material litigation was reported. The auditor gave an unqualified opinion on the financial statements; management assessed internal controls as effective, while the auditor did not opine on their effectiveness.
Important facts for investors to verify
- Whether the alternate DetermaVu platform was selected and whether analytical and clinical validation met prespecified performance criteria.
- Whether the remaining $2.0 million from the March 2018 private placement was received, and the company’s subsequent cash runway, burn rate, and financing needs.
- Whether DetermaVu obtained required state laboratory permissions, payer coverage, adequate reimbursement, and physician adoption before any commercial launch.
- The current status of the $1.87 million bank loan, capital leases, and $2.10 million payable to BioTime and affiliates, including collateral and related-party allocation terms.
- Potential dilution from outstanding warrants and options; year-end warrants covered 2.78 million shares, and options covered 3.39 million shares.